The firm has launched new Phadia 2500E Laboratory System that can analyze up to 25,000 samples per week, allowing clinical labs to provide patient test results quickly and accurately.
It has been designed to detect and quantify relevant antibodies in blood samples to identify possible allergy or autoimmune sensitivity.
The company has also expanded its allergy test kits portfolio with the addition of ImmunoCAP Allergen Components for hazelnut and cashew nuts, helping to identify patients who may have potentially serious reactions to a wider variety of food products.
At the event, the firm has also launched new FDA 510(k) cleared immunoassays to detect autoimmune disorders.
The EliA PR3, EliA MPO and EliA GBM assays will measure auto-antibodies to diagnose ANCA Vasculitis, Goodpasture Syndrome and associated conditions, which typically result in kidney disease.
The company has launched MAS Liquimmune multi-analyte controls, which are claimed to be first quality control standards for clinical chemistry with a shelf life of five years.
Thermo Scientific Prelude LX-4 MD HPLC is recognized as a class I medical device by FDA for general clinical use for in vitro diagnostics. It features four parallel channels that can deliver up to four different separations to a single mass spectrometer with identical or different methods to enhance sample throughput.
The company is also providing instruments and consumables to research being undertaken by AACC, which is collecting serum/plasma samples from healthy adults attending the show through its Blood Sample Bank to enable a direct comparison of troponin assays.
